distinguishes

Crypto.com Surpasses 100 Million Global Users

New Major Milestone Reached Following Latest Marketing Campaign Sydney, May 6, 2024 - Crypto.com today announced it has surpassed the 100 million global user mark – the latest significant milestone for the company founded in 2016 and the industry leader in regulatory compliance, security and privacy. This milestone was reached in the immediate wake of Crypto.com’s latest Fortune Favors the Brave brand film, INEVITABLE, which celebrates conviction, achievement against all odds and staying focused on the additional goals ahead. Crypto.com’s user base has doubled since the first Formula 1 Crypto.com

Simplifying and Elevating GraphQL to New Heights: Grafbase’s Strategic Leap in Enterprise Adoption

~ Grafbase is leading the GraphQL revolution by providing a modern developer experience for building and deploying high-performance APIs. ~ With the advent of Federated Graphs, Grafbase allows composing multiple, independently deployed GraphQL APIs into a single endpoint. ~ The platform sets new standards in the GraphQL ecosystem with TypeScript SDK, Edge Caching, advanced security, real-time analytics, and more. March 2024: According to a report by Gartner, the adoption of GraphQL has been on an increasing trend, from less than 10% in 2021 to over 50% by 2025. Demand for

Tokens Fueling Innovation in the Dynamic Fantom DeFi Ecosystem

In the rapidly evolving realm of Defi and L1’s, the Fantom ecosystem shines as a vibrant hub for innovation. Within this dynamic landscape, various protocols play pivotal roles in sculpting the future of decentralized finance on Fantom. Each protocol brings its distinct features, vision, and potential to the forefront, propelling growth, stability, and inclusivity within the Fantom DeFi ecosystem. The most known protocol in Fantom is SpookySwap (Ticker : BOO), an EVM-compatible DEX, has been pioneered since its April 2021 launch. Endorsed by the Fantom Foundation and bolstered by community

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced